#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Metabolic syndrome ( MetS ) is a cluster of disorders , including insulin resistance/hyperglycemia , visceral adiposity [ identified by large waistline ( WL ) or being overweight ] , atherogenic dyslipidemia ( e.g. , raised triglycerides ( TG ) or reduced high-density lipoprotein ( HDL ) ) , and endothelial dysfunction ( characterized by elevated blood pressures ) .
2-1	16-25	Metabolic	person|abstract[3]	new|new[3]	appos	2-4[0_3]
2-2	26-34	syndrome	abstract[3]	new[3]	_	_
2-3	35-36	(	_	_	_	_
2-4	37-41	MetS	abstract	giv	coref	2-7[5_0]
2-5	42-43	)	_	_	_	_
2-6	44-46	is	_	_	_	_
2-7	47-48	a	abstract[5]	giv[5]	coref	3-1[0_5]
2-8	49-56	cluster	abstract[5]	giv[5]	_	_
2-9	57-59	of	abstract[5]	giv[5]	_	_
2-10	60-69	disorders	abstract[5]|abstract[6]	giv[5]|new[6]	coref	13-47[132_6]
2-11	70-71	,	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-12	72-81	including	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-13	82-89	insulin	abstract[5]|abstract[6]|substance|abstract[8]	giv[5]|new[6]|new|new[8]	_	_
2-14	90-114	resistance/hyperglycemia	abstract[5]|abstract[6]|abstract[8]	giv[5]|new[6]|new[8]	_	_
2-15	115-116	,	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-16	117-125	visceral	abstract[5]|abstract[6]|abstract[9]	giv[5]|new[6]|new[9]	_	_
2-17	126-135	adiposity	abstract[5]|abstract[6]|abstract[9]	giv[5]|new[6]|new[9]	_	_
2-18	136-137	[	abstract[5]|abstract[6]|abstract[9]	giv[5]|new[6]|new[9]	_	_
2-19	138-148	identified	abstract[5]|abstract[6]|abstract[9]	giv[5]|new[6]|new[9]	_	_
2-20	149-151	by	abstract[5]|abstract[6]|abstract[9]	giv[5]|new[6]|new[9]	_	_
2-21	152-157	large	abstract[5]|abstract[6]|abstract[9]|abstract[10]	giv[5]|new[6]|new[9]|new[10]	appos	2-24[0_10]
2-22	158-167	waistline	abstract[5]|abstract[6]|abstract[9]|abstract[10]	giv[5]|new[6]|new[9]|new[10]	_	_
2-23	168-169	(	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-24	170-172	WL	abstract[5]|abstract[6]|abstract	giv[5]|new[6]|giv	_	_
2-25	173-174	)	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-26	175-177	or	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-27	178-183	being	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-28	184-194	overweight	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-29	195-196	]	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-30	197-198	,	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-31	199-210	atherogenic	abstract[5]|abstract[6]|abstract[12]	giv[5]|new[6]|new[12]	_	_
2-32	211-223	dyslipidemia	abstract[5]|abstract[6]|abstract[12]	giv[5]|new[6]|new[12]	_	_
2-33	224-225	(	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-34	226-230	e.g.	abstract[5]|abstract[6]|substance[13]	giv[5]|new[6]|new[13]	_	_
2-35	231-232	,	abstract[5]|abstract[6]|substance[13]	giv[5]|new[6]|new[13]	_	_
2-36	233-239	raised	abstract[5]|abstract[6]|substance[13]	giv[5]|new[6]|new[13]	_	_
2-37	240-253	triglycerides	abstract[5]|abstract[6]|substance[13]	giv[5]|new[6]|new[13]	_	_
2-38	254-255	(	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-39	256-258	TG	abstract[5]|abstract[6]|abstract	giv[5]|new[6]|new	_	_
2-40	259-260	)	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-41	261-263	or	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-42	264-271	reduced	abstract[5]|abstract[6]|substance[15]	giv[5]|new[6]|new[15]	_	_
2-43	272-284	high-density	abstract[5]|abstract[6]|substance[15]	giv[5]|new[6]|new[15]	_	_
2-44	285-296	lipoprotein	abstract[5]|abstract[6]|substance[15]	giv[5]|new[6]|new[15]	_	_
2-45	297-298	(	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-46	299-302	HDL	abstract[5]|abstract[6]|abstract	giv[5]|new[6]|new	_	_
2-47	303-304	)	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-48	305-306	)	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-49	307-308	,	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-50	309-312	and	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-51	313-324	endothelial	abstract[5]|abstract[6]|abstract[17]	giv[5]|new[6]|new[17]	_	_
2-52	325-336	dysfunction	abstract[5]|abstract[6]|abstract[17]	giv[5]|new[6]|new[17]	_	_
2-53	337-338	(	abstract[5]|abstract[6]|abstract[17]	giv[5]|new[6]|new[17]	_	_
2-54	339-352	characterized	abstract[5]|abstract[6]|abstract[17]	giv[5]|new[6]|new[17]	_	_
2-55	353-355	by	abstract[5]|abstract[6]|abstract[17]	giv[5]|new[6]|new[17]	_	_
2-56	356-364	elevated	abstract[5]|abstract[6]|abstract[17]|abstract[19]	giv[5]|new[6]|new[17]|new[19]	_	_
2-57	365-370	blood	abstract[5]|abstract[6]|abstract[17]|substance|abstract[19]	giv[5]|new[6]|new[17]|new|new[19]	coref	5-14
2-58	371-380	pressures	abstract[5]|abstract[6]|abstract[17]|abstract[19]	giv[5]|new[6]|new[17]|new[19]	_	_
2-59	381-382	)	abstract[5]|abstract[6]|abstract[17]	giv[5]|new[6]|new[17]	_	_
2-60	383-384	.	_	_	_	_

#Text=MetS significantly influences the development and deterioration of numerous diseases and is a crucial predictor of cardiovascular diseases .
3-1	385-389	MetS	abstract	giv	coref	4-13
3-2	390-403	significantly	_	_	_	_
3-3	404-414	influences	_	_	_	_
3-4	415-418	the	event[21]	new[21]	_	_
3-5	419-430	development	event[21]	new[21]	_	_
3-6	431-434	and	_	_	_	_
3-7	435-448	deterioration	abstract[22]	new[22]	_	_
3-8	449-451	of	abstract[22]	new[22]	_	_
3-9	452-460	numerous	abstract[22]|abstract[23]	new[22]|new[23]	coref	3-17[25_23]
3-10	461-469	diseases	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-11	470-473	and	_	_	_	_
3-12	474-476	is	_	_	_	_
3-13	477-478	a	abstract[24]	new[24]	ana	4-20[0_24]
3-14	479-486	crucial	abstract[24]	new[24]	_	_
3-15	487-496	predictor	abstract[24]	new[24]	_	_
3-16	497-499	of	abstract[24]	new[24]	_	_
3-17	500-514	cardiovascular	abstract[24]|abstract[25]	new[24]|giv[25]	coref	4-39[37_25]
3-18	515-523	diseases	abstract[24]|abstract[25]	new[24]|giv[25]	_	_
3-19	524-525	.	_	_	_	_

#Text=Fortunately , numerous modifiable risk factors and corresponding practical intervention strategies regarding MetS were proposed , and hence , it is vital to identify the high-risk individuals nowadays to prevent the incidence and deterioration of metabolic derangement and its associated diseases .
4-1	526-537	Fortunately	_	_	_	_
4-2	538-539	,	_	_	_	_
4-3	540-548	numerous	abstract[27]	new[27]	_	_
4-4	549-559	modifiable	abstract[27]	new[27]	_	_
4-5	560-564	risk	abstract|abstract[27]	new|new[27]	_	_
4-6	565-572	factors	abstract[27]	new[27]	_	_
4-7	573-576	and	_	_	_	_
4-8	577-590	corresponding	abstract[29]	new[29]	_	_
4-9	591-600	practical	abstract[29]	new[29]	_	_
4-10	601-613	intervention	event|abstract[29]	new|new[29]	_	_
4-11	614-624	strategies	abstract[29]	new[29]	_	_
4-12	625-634	regarding	abstract[29]	new[29]	_	_
4-13	635-639	MetS	abstract[29]|abstract	new[29]|giv	coref	5-10
4-14	640-644	were	_	_	_	_
4-15	645-653	proposed	_	_	_	_
4-16	654-655	,	_	_	_	_
4-17	656-659	and	_	_	_	_
4-18	660-665	hence	_	_	_	_
4-19	666-667	,	_	_	_	_
4-20	668-670	it	abstract	giv	ana	4-39
4-21	671-673	is	_	_	_	_
4-22	674-679	vital	_	_	_	_
4-23	680-682	to	_	_	_	_
4-24	683-691	identify	_	_	_	_
4-25	692-695	the	person[32]	new[32]	_	_
4-26	696-705	high-risk	person[32]	new[32]	_	_
4-27	706-717	individuals	person[32]	new[32]	_	_
4-28	718-726	nowadays	_	_	_	_
4-29	727-729	to	_	_	_	_
4-30	730-737	prevent	_	_	_	_
4-31	738-741	the	abstract[33]	new[33]	_	_
4-32	742-751	incidence	abstract[33]	new[33]	_	_
4-33	752-755	and	_	_	_	_
4-34	756-769	deterioration	abstract[34]	new[34]	_	_
4-35	770-772	of	abstract[34]	new[34]	_	_
4-36	773-782	metabolic	abstract[34]|abstract[35]	new[34]|new[35]	_	_
4-37	783-794	derangement	abstract[34]|abstract[35]	new[34]|new[35]	_	_
4-38	795-798	and	abstract[34]	new[34]	_	_
4-39	799-802	its	abstract[34]|abstract|abstract[37]	new[34]|giv|giv[37]	_	_
4-40	803-813	associated	abstract[34]|abstract[37]	new[34]|giv[37]	_	_
4-41	814-822	diseases	abstract[34]|abstract[37]	new[34]|giv[37]	_	_
4-42	823-824	.	_	_	_	_

#Text=Nevertheless , the conventional procedures for the confirmation of MetS have depended on blood assays , which largely lead to a resistive mentality toward the procedures and are therefore nonconducive to long-term follow-up .
5-1	825-837	Nevertheless	_	_	_	_
5-2	838-839	,	_	_	_	_
5-3	840-843	the	abstract[38]	new[38]	coref	5-25[44_38]
5-4	844-856	conventional	abstract[38]	new[38]	_	_
5-5	857-867	procedures	abstract[38]	new[38]	_	_
5-6	868-871	for	abstract[38]	new[38]	_	_
5-7	872-875	the	abstract[38]|event[39]	new[38]|new[39]	_	_
5-8	876-888	confirmation	abstract[38]|event[39]	new[38]|new[39]	_	_
5-9	889-891	of	abstract[38]|event[39]	new[38]|new[39]	_	_
5-10	892-896	MetS	abstract[38]|event[39]|abstract	new[38]|new[39]|giv	coref	6-10
5-11	897-901	have	_	_	_	_
5-12	902-910	depended	_	_	_	_
5-13	911-913	on	_	_	_	_
5-14	914-919	blood	substance|abstract[42]	giv|new[42]	coref|coref	22-24|22-24[226_42]
5-15	920-926	assays	abstract[42]	new[42]	_	_
5-16	927-928	,	abstract[42]	new[42]	_	_
5-17	929-934	which	abstract[42]	new[42]	_	_
5-18	935-942	largely	abstract[42]	new[42]	_	_
5-19	943-947	lead	abstract[42]	new[42]	_	_
5-20	948-950	to	abstract[42]	new[42]	_	_
5-21	951-952	a	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-22	953-962	resistive	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-23	963-972	mentality	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-24	973-979	toward	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-25	980-983	the	abstract[42]|abstract[43]|abstract[44]	new[42]|new[43]|giv[44]	coref	22-17[224_44]
5-26	984-994	procedures	abstract[42]|abstract[43]|abstract[44]	new[42]|new[43]|giv[44]	_	_
5-27	995-998	and	abstract[42]	new[42]	_	_
5-28	999-1002	are	abstract[42]	new[42]	_	_
5-29	1003-1012	therefore	abstract[42]	new[42]	_	_
5-30	1013-1025	nonconducive	abstract[42]	new[42]	_	_
5-31	1026-1028	to	_	_	_	_
5-32	1029-1038	long-term	event[45]	new[45]	_	_
5-33	1039-1048	follow-up	event[45]	new[45]	_	_
5-34	1049-1050	.	_	_	_	_

#Text=Therefore , there is a high probability of the MetS population being under-identified , especially those without an obese body shape .
6-1	1051-1060	Therefore	_	_	_	_
6-2	1061-1062	,	_	_	_	_
6-3	1063-1068	there	_	_	_	_
6-4	1069-1071	is	_	_	_	_
6-5	1072-1073	a	abstract[46]	new[46]	_	_
6-6	1074-1078	high	abstract[46]	new[46]	_	_
6-7	1079-1090	probability	abstract[46]	new[46]	_	_
6-8	1091-1093	of	abstract[46]	new[46]	_	_
6-9	1094-1097	the	abstract[46]|person[48]	new[46]|new[48]	coref	14-19[0_48]
6-10	1098-1102	MetS	abstract[46]|abstract|person[48]	new[46]|giv|new[48]	coref	7-18
6-11	1103-1113	population	abstract[46]|person[48]	new[46]|new[48]	_	_
6-12	1114-1119	being	abstract[46]	new[46]	_	_
6-13	1120-1136	under-identified	abstract[46]	new[46]	_	_
6-14	1137-1138	,	_	_	_	_
6-15	1139-1149	especially	_	_	_	_
6-16	1150-1155	those	_	_	_	_
6-17	1156-1163	without	_	_	_	_
6-18	1164-1166	an	abstract[50]	new[50]	_	_
6-19	1167-1172	obese	abstract[50]	new[50]	_	_
6-20	1173-1177	body	object|abstract[50]	new|new[50]	_	_
6-21	1178-1183	shape	abstract[50]	new[50]	_	_
6-22	1184-1185	.	_	_	_	_

#Text=Consequently , there is a medical need for an easy , fast , and non-invasive method for MetS screening .
7-1	1186-1198	Consequently	_	_	_	_
7-2	1199-1200	,	_	_	_	_
7-3	1201-1206	there	_	_	_	_
7-4	1207-1209	is	_	_	_	_
7-5	1210-1211	a	abstract[51]	new[51]	_	_
7-6	1212-1219	medical	abstract[51]	new[51]	_	_
7-7	1220-1224	need	abstract[51]	new[51]	_	_
7-8	1225-1228	for	abstract[51]	new[51]	_	_
7-9	1229-1231	an	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-10	1232-1236	easy	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-11	1237-1238	,	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-12	1239-1243	fast	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-13	1244-1245	,	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-14	1246-1249	and	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-15	1250-1262	non-invasive	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-16	1263-1269	method	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-17	1270-1273	for	abstract[51]|abstract[52]	new[51]|new[52]	_	_
7-18	1274-1278	MetS	abstract[51]|abstract[52]|abstract|event[54]	new[51]|new[52]|giv|new[54]	coref|coref	14-19[141_54]|18-19[177_0]
7-19	1279-1288	screening	abstract[51]|abstract[52]|event[54]	new[51]|new[52]|new[54]	_	_
7-20	1289-1290	.	_	_	_	_

#Text=FibroScan is an ultrasound-based device equipped with the naval patented technology — Vibration-Controlled Transient Elastography ( VCTETM ) — that was originally developed to assess the level of liver fibrosis and cirrhosis by using a liver stiffness score ( the E score ) .
8-1	1291-1300	FibroScan	object	new	coref	8-3[56_0]
8-2	1301-1303	is	_	_	_	_
8-3	1304-1306	an	object[56]	giv[56]	coref	9-55[90_56]
8-4	1307-1323	ultrasound-based	object[56]	giv[56]	_	_
8-5	1324-1330	device	object[56]	giv[56]	_	_
8-6	1331-1339	equipped	object[56]	giv[56]	_	_
8-7	1340-1344	with	object[56]	giv[56]	_	_
8-8	1345-1348	the	object[56]|abstract[57]	giv[56]|new[57]	_	_
8-9	1349-1354	naval	object[56]|abstract[57]	giv[56]|new[57]	_	_
8-10	1355-1363	patented	object[56]|abstract[57]	giv[56]|new[57]	_	_
8-11	1364-1374	technology	object[56]|abstract[57]	giv[56]|new[57]	_	_
8-12	1375-1376	—	_	_	_	_
8-13	1377-1397	Vibration-Controlled	abstract|object[60]	new|new[60]	_	_
8-14	1398-1407	Transient	person|object[60]	new|new[60]	_	_
8-15	1408-1420	Elastography	object[60]	new[60]	_	_
8-16	1421-1422	(	_	_	_	_
8-17	1423-1429	VCTETM	abstract	new	_	_
8-18	1430-1431	)	_	_	_	_
8-19	1432-1433	—	_	_	_	_
8-20	1434-1438	that	_	_	_	_
8-21	1439-1442	was	_	_	_	_
8-22	1443-1453	originally	_	_	_	_
8-23	1454-1463	developed	_	_	_	_
8-24	1464-1466	to	_	_	_	_
8-25	1467-1473	assess	_	_	_	_
8-26	1474-1477	the	abstract[62]	new[62]	_	_
8-27	1478-1483	level	abstract[62]	new[62]	_	_
8-28	1484-1486	of	abstract[62]	new[62]	_	_
8-29	1487-1492	liver	abstract[62]|object|object[64]	new[62]|new|new[64]	coref	8-36
8-30	1493-1501	fibrosis	abstract[62]|object[64]	new[62]|new[64]	_	_
8-31	1502-1505	and	abstract[62]	new[62]	_	_
8-32	1506-1515	cirrhosis	abstract[62]|abstract	new[62]|new	_	_
8-33	1516-1518	by	_	_	_	_
8-34	1519-1524	using	_	_	_	_
8-35	1525-1526	a	abstract[68]	new[68]	coref	9-14[78_68]
8-36	1527-1532	liver	object|abstract[68]	giv|new[68]	coref	9-47
8-37	1533-1542	stiffness	abstract|abstract[68]	new|new[68]	coref	9-7[73_0]
8-38	1543-1548	score	abstract[68]	new[68]	_	_
8-39	1549-1550	(	_	_	_	_
8-40	1551-1554	the	_	_	_	_
8-41	1555-1556	E	abstract	new	coref	9-15
8-42	1557-1562	score	_	_	_	_
8-43	1563-1564	)	_	_	_	_
8-44	1565-1566	.	_	_	_	_

#Text=Based on the transformation function of media stiffness and wave transmission velocity , the E score is calculated using a series of elastograms , which are simulated graphics of mathematical function of the time and depth of at least 10 shots of shear waves propagating through liver parenchyma transmitted using the probes mounted on the device .
9-1	1567-1572	Based	_	_	_	_
9-2	1573-1575	on	_	_	_	_
9-3	1576-1579	the	abstract[71]	new[71]	_	_
9-4	1580-1594	transformation	abstract|abstract[71]	new|new[71]	coref	10-6[94_0]
9-5	1595-1603	function	abstract[71]	new[71]	_	_
9-6	1604-1606	of	abstract[71]	new[71]	_	_
9-7	1607-1612	media	abstract[71]|substance|abstract[73]	new[71]|new|giv[73]	_	_
9-8	1613-1622	stiffness	abstract[71]|abstract[73]	new[71]|giv[73]	_	_
9-9	1623-1626	and	abstract[71]	new[71]	_	_
9-10	1627-1631	wave	abstract[71]|abstract|abstract[75]|abstract[76]	new[71]|new|new[75]|new[76]	coref	10-1[92_0]
9-11	1632-1644	transmission	abstract[71]|abstract[75]|abstract[76]	new[71]|new[75]|new[76]	_	_
9-12	1645-1653	velocity	abstract[71]|abstract[76]	new[71]|new[76]	_	_
9-13	1654-1655	,	_	_	_	_
9-14	1656-1659	the	abstract[78]	giv[78]	coref	11-1[106_78]
9-15	1660-1661	E	abstract|abstract[78]	giv|giv[78]	coref	12-16
9-16	1662-1667	score	abstract[78]	giv[78]	_	_
9-17	1668-1670	is	_	_	_	_
9-18	1671-1681	calculated	_	_	_	_
9-19	1682-1687	using	_	_	_	_
9-20	1688-1689	a	abstract[79]	new[79]	_	_
9-21	1690-1696	series	abstract[79]	new[79]	_	_
9-22	1697-1699	of	abstract[79]	new[79]	_	_
9-23	1700-1711	elastograms	abstract[79]|abstract[80]	new[79]|new[80]	_	_
9-24	1712-1713	,	abstract[79]|abstract[80]	new[79]|new[80]	_	_
9-25	1714-1719	which	abstract[79]|abstract[80]|abstract[81]	new[79]|new[80]|new[81]	_	_
9-26	1720-1723	are	abstract[79]|abstract[80]|abstract[81]	new[79]|new[80]|new[81]	_	_
9-27	1724-1733	simulated	abstract[79]|abstract[80]|abstract[81]	new[79]|new[80]|new[81]	_	_
9-28	1734-1742	graphics	abstract[79]|abstract[80]|abstract[81]	new[79]|new[80]|new[81]	_	_
9-29	1743-1745	of	abstract[79]|abstract[80]|abstract[81]	new[79]|new[80]|new[81]	_	_
9-30	1746-1758	mathematical	abstract[79]|abstract[80]|abstract[81]|abstract[82]	new[79]|new[80]|new[81]|new[82]	_	_
9-31	1759-1767	function	abstract[79]|abstract[80]|abstract[81]|abstract[82]	new[79]|new[80]|new[81]|new[82]	_	_
9-32	1768-1770	of	abstract[79]|abstract[80]|abstract[81]|abstract[82]	new[79]|new[80]|new[81]|new[82]	_	_
9-33	1771-1774	the	abstract[79]|abstract[80]|abstract[81]|abstract[82]|time[83]	new[79]|new[80]|new[81]|new[82]|new[83]	_	_
9-34	1775-1779	time	abstract[79]|abstract[80]|abstract[81]|abstract[82]|time[83]	new[79]|new[80]|new[81]|new[82]|new[83]	_	_
9-35	1780-1783	and	abstract[79]|abstract[80]|abstract[81]|abstract[82]	new[79]|new[80]|new[81]|new[82]	_	_
9-36	1784-1789	depth	abstract[79]|abstract[80]|abstract[81]|abstract[82]|abstract	new[79]|new[80]|new[81]|new[82]|new	_	_
9-37	1790-1792	of	abstract[79]|abstract[80]|abstract[81]|abstract[82]	new[79]|new[80]|new[81]|new[82]	_	_
9-38	1793-1795	at	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]	new[79]|new[80]|new[81]|new[82]|new[85]	_	_
9-39	1796-1801	least	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]	new[79]|new[80]|new[81]|new[82]|new[85]	_	_
9-40	1802-1804	10	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]	new[79]|new[80]|new[81]|new[82]|new[85]	_	_
9-41	1805-1810	shots	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]	new[79]|new[80]|new[81]|new[82]|new[85]	_	_
9-42	1811-1813	of	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]	new[79]|new[80]|new[81]|new[82]|new[85]	_	_
9-43	1814-1819	shear	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]	coref	12-10[114_86]
9-44	1820-1825	waves	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]	_	_
9-45	1826-1837	propagating	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]	_	_
9-46	1838-1845	through	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]	_	_
9-47	1846-1851	liver	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]|object|object[88]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]|giv|new[88]	coref	10-23
9-48	1852-1862	parenchyma	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]|object[88]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]|new[88]	_	_
9-49	1863-1874	transmitted	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]	_	_
9-50	1875-1880	using	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]	_	_
9-51	1881-1884	the	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]|object[89]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]|new[89]	_	_
9-52	1885-1891	probes	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]|object[89]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]|new[89]	_	_
9-53	1892-1899	mounted	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]|object[89]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]|new[89]	_	_
9-54	1900-1902	on	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]|object[89]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]|new[89]	_	_
9-55	1903-1906	the	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]|object[89]|object[90]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]|new[89]|giv[90]	coref	13-41[0_90]
9-56	1907-1913	device	abstract[79]|abstract[80]|abstract[81]|abstract[82]|object[85]|abstract[86]|object[89]|object[90]	new[79]|new[80]|new[81]|new[82]|new[85]|new[86]|new[89]|giv[90]	_	_
9-57	1914-1915	.	_	_	_	_

#Text=The multiple-shot shear wave and elastogram transformation are implemented with controlled vibration , energy , and algorithms on the identical volume of liver tissue to ensure measurement reliability .
10-1	1916-1919	The	abstract[92]	giv[92]	_	_
10-2	1920-1933	multiple-shot	abstract[92]	giv[92]	_	_
10-3	1934-1939	shear	substance|abstract[92]	new|giv[92]	_	_
10-4	1940-1944	wave	abstract[92]	giv[92]	_	_
10-5	1945-1948	and	_	_	_	_
10-6	1949-1959	elastogram	abstract|abstract[94]	new|giv[94]	_	_
10-7	1960-1974	transformation	abstract[94]	giv[94]	_	_
10-8	1975-1978	are	_	_	_	_
10-9	1979-1990	implemented	_	_	_	_
10-10	1991-1995	with	_	_	_	_
10-11	1996-2006	controlled	abstract[95]	new[95]	_	_
10-12	2007-2016	vibration	abstract[95]	new[95]	_	_
10-13	2017-2018	,	_	_	_	_
10-14	2019-2025	energy	abstract	new	_	_
10-15	2026-2027	,	_	_	_	_
10-16	2028-2031	and	_	_	_	_
10-17	2032-2042	algorithms	abstract[97]	new[97]	_	_
10-18	2043-2045	on	abstract[97]	new[97]	_	_
10-19	2046-2049	the	abstract[97]|abstract[98]	new[97]|new[98]	_	_
10-20	2050-2059	identical	abstract[97]|abstract[98]	new[97]|new[98]	_	_
10-21	2060-2066	volume	abstract[97]|abstract[98]	new[97]|new[98]	_	_
10-22	2067-2069	of	abstract[97]|abstract[98]	new[97]|new[98]	_	_
10-23	2070-2075	liver	abstract[97]|abstract[98]|object|object[100]	new[97]|new[98]|giv|new[100]	coref	11-12
10-24	2076-2082	tissue	abstract[97]|abstract[98]|object[100]	new[97]|new[98]|new[100]	_	_
10-25	2083-2085	to	_	_	_	_
10-26	2086-2092	ensure	_	_	_	_
10-27	2093-2104	measurement	abstract|abstract[102]	new|new[102]	coref|coref	12-15[117_0]|22-10[0_102]
10-28	2105-2116	reliability	abstract[102]	new[102]	_	_
10-29	2117-2118	.	_	_	_	_

#Text=The controlled attenuation parameter ( CAP ) score , denoting the liver steatosis , was embedded in instruments marketed after 2013 .
11-1	2119-2122	The	abstract[106]	giv[106]	coref	12-1[111_106]
11-2	2123-2133	controlled	abstract[104]|abstract[106]	new[104]|giv[106]	appos	11-6[0_104]
11-3	2134-2145	attenuation	abstract|abstract[104]|abstract[106]	new|new[104]|giv[106]	_	_
11-4	2146-2155	parameter	abstract[104]|abstract[106]	new[104]|giv[106]	_	_
11-5	2156-2157	(	abstract[106]	giv[106]	_	_
11-6	2158-2161	CAP	abstract|abstract[106]	giv|giv[106]	coref	16-12
11-7	2162-2163	)	abstract[106]	giv[106]	_	_
11-8	2164-2169	score	abstract[106]	giv[106]	_	_
11-9	2170-2171	,	abstract[106]	giv[106]	_	_
11-10	2172-2180	denoting	abstract[106]	giv[106]	_	_
11-11	2181-2184	the	abstract[106]|abstract[108]	giv[106]|new[108]	coref	16-7[0_108]
11-12	2185-2190	liver	abstract[106]|object|abstract[108]	giv[106]|giv|new[108]	coref	13-49
11-13	2191-2200	steatosis	abstract[106]|abstract[108]	giv[106]|new[108]	_	_
11-14	2201-2202	,	_	_	_	_
11-15	2203-2206	was	_	_	_	_
11-16	2207-2215	embedded	_	_	_	_
11-17	2216-2218	in	_	_	_	_
11-18	2219-2230	instruments	object[109]	new[109]	_	_
11-19	2231-2239	marketed	object[109]	new[109]	_	_
11-20	2240-2245	after	object[109]	new[109]	_	_
11-21	2246-2250	2013	object[109]|time	new[109]|new	_	_
11-22	2251-2252	.	_	_	_	_

#Text=The score is derived from the amplitude attenuations of ultrasonic waves detected simultaneously from the E score measurement .
12-1	2253-2256	The	abstract[111]	giv[111]	coref	12-16[116_111]
12-2	2257-2262	score	abstract[111]	giv[111]	_	_
12-3	2263-2265	is	_	_	_	_
12-4	2266-2273	derived	_	_	_	_
12-5	2274-2278	from	_	_	_	_
12-6	2279-2282	the	abstract[113]	new[113]	_	_
12-7	2283-2292	amplitude	abstract|abstract[113]	new|new[113]	_	_
12-8	2293-2305	attenuations	abstract[113]	new[113]	_	_
12-9	2306-2308	of	abstract[113]	new[113]	_	_
12-10	2309-2319	ultrasonic	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
12-11	2320-2325	waves	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
12-12	2326-2334	detected	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
12-13	2335-2349	simultaneously	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
12-14	2350-2354	from	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
12-15	2355-2358	the	abstract[113]|abstract[114]|abstract[117]	new[113]|giv[114]|giv[117]	ana	13-3[0_117]
12-16	2359-2360	E	abstract[113]|abstract[114]|abstract|abstract[116]|abstract[117]	new[113]|giv[114]|giv|giv[116]|giv[117]	coref	16-12[159_116]
12-17	2361-2366	score	abstract[113]|abstract[114]|abstract[116]|abstract[117]	new[113]|giv[114]|giv[116]|giv[117]	_	_
12-18	2367-2378	measurement	abstract[113]|abstract[114]|abstract[117]	new[113]|giv[114]|giv[117]	_	_
12-19	2379-2380	.	_	_	_	_

#Text=Owing to its merits of being noninvasive , safe , rapid ( approximately 5 – 10 min for application ) , and the high-reproducibility of its automatically quantitative assessment outputs among operators , numerous studies have evaluated the performance of FibroScan in detecting chronic hepatitis and various other liver disorders .
13-1	2381-2386	Owing	_	_	_	_
13-2	2387-2389	to	_	_	_	_
13-3	2390-2393	its	abstract|abstract[119]	giv|new[119]	ana|coref	13-26|17-8[0_119]
13-4	2394-2400	merits	abstract[119]	new[119]	_	_
13-5	2401-2403	of	abstract[119]	new[119]	_	_
13-6	2404-2409	being	abstract[119]	new[119]	_	_
13-7	2410-2421	noninvasive	abstract[119]	new[119]	_	_
13-8	2422-2423	,	abstract[119]	new[119]	_	_
13-9	2424-2428	safe	abstract[119]	new[119]	_	_
13-10	2429-2430	,	abstract[119]	new[119]	_	_
13-11	2431-2436	rapid	abstract[119]	new[119]	_	_
13-12	2437-2438	(	abstract[119]	new[119]	_	_
13-13	2439-2452	approximately	abstract[119]|time[120]	new[119]|new[120]	_	_
13-14	2453-2454	5	abstract[119]|time[120]	new[119]|new[120]	_	_
13-15	2455-2456	–	abstract[119]|time[120]	new[119]|new[120]	_	_
13-16	2457-2459	10	abstract[119]|time[120]	new[119]|new[120]	_	_
13-17	2460-2463	min	abstract[119]|time[120]	new[119]|new[120]	_	_
13-18	2464-2467	for	abstract[119]|time[120]	new[119]|new[120]	_	_
13-19	2468-2479	application	abstract[119]|time[120]|abstract	new[119]|new[120]|new	_	_
13-20	2480-2481	)	abstract[119]	new[119]	_	_
13-21	2482-2483	,	abstract[119]	new[119]	_	_
13-22	2484-2487	and	abstract[119]	new[119]	_	_
13-23	2488-2491	the	abstract[119]|abstract[122]	new[119]|new[122]	_	_
13-24	2492-2512	high-reproducibility	abstract[119]|abstract[122]	new[119]|new[122]	_	_
13-25	2513-2515	of	abstract[119]|abstract[122]	new[119]|new[122]	_	_
13-26	2516-2519	its	abstract[119]|abstract[122]|abstract|abstract[125]	new[119]|new[122]|giv|new[125]	_	_
13-27	2520-2533	automatically	abstract[119]|abstract[122]|abstract[125]	new[119]|new[122]|new[125]	_	_
13-28	2534-2546	quantitative	abstract[119]|abstract[122]|abstract[125]	new[119]|new[122]|new[125]	_	_
13-29	2547-2557	assessment	abstract[119]|abstract[122]|abstract|abstract[125]	new[119]|new[122]|new|new[125]	coref	17-27[167_0]
13-30	2558-2565	outputs	abstract[119]|abstract[122]|abstract[125]	new[119]|new[122]|new[125]	_	_
13-31	2566-2571	among	abstract[119]|abstract[122]	new[119]|new[122]	_	_
13-32	2572-2581	operators	abstract[119]|abstract[122]|person	new[119]|new[122]|new	_	_
13-33	2582-2583	,	_	_	_	_
13-34	2584-2592	numerous	abstract[127]	new[127]	coref	16-1[152_127]
13-35	2593-2600	studies	abstract[127]	new[127]	_	_
13-36	2601-2605	have	_	_	_	_
13-37	2606-2615	evaluated	_	_	_	_
13-38	2616-2619	the	abstract[128]	new[128]	_	_
13-39	2620-2631	performance	abstract[128]	new[128]	_	_
13-40	2632-2634	of	abstract[128]	new[128]	_	_
13-41	2635-2644	FibroScan	abstract[128]|object	new[128]|giv	coref	17-3
13-42	2645-2647	in	_	_	_	_
13-43	2648-2657	detecting	_	_	_	_
13-44	2658-2665	chronic	abstract[130]	new[130]	coref	15-6[0_130]
13-45	2666-2675	hepatitis	abstract[130]	new[130]	_	_
13-46	2676-2679	and	_	_	_	_
13-47	2680-2687	various	abstract[132]	giv[132]	coref	16-17[162_132]
13-48	2688-2693	other	abstract[132]	giv[132]	_	_
13-49	2694-2699	liver	object|abstract[132]	giv|giv[132]	coref	16-6
13-50	2700-2709	disorders	abstract[132]	giv[132]	_	_
13-51	2710-2711	.	_	_	_	_

#Text=In addition to bedside inspection in hospitalized patients , the virtue of its portability was also manifested in population outreach screening .
14-1	2712-2714	In	_	_	_	_
14-2	2715-2723	addition	_	_	_	_
14-3	2724-2726	to	_	_	_	_
14-4	2727-2734	bedside	place|event[134]	new|new[134]	_	_
14-5	2735-2745	inspection	event[134]	new[134]	_	_
14-6	2746-2748	in	event[134]	new[134]	_	_
14-7	2749-2761	hospitalized	event[134]|person[135]	new[134]|new[135]	coref	16-15[160_135]
14-8	2762-2770	patients	event[134]|person[135]	new[134]|new[135]	_	_
14-9	2771-2772	,	_	_	_	_
14-10	2773-2776	the	abstract[136]	new[136]	ana	14-13[0_136]
14-11	2777-2783	virtue	abstract[136]	new[136]	_	_
14-12	2784-2786	of	abstract[136]	new[136]	_	_
14-13	2787-2790	its	abstract[136]|abstract|abstract[138]	new[136]|giv|new[138]	_	_
14-14	2791-2802	portability	abstract[136]|abstract[138]	new[136]|new[138]	_	_
14-15	2803-2806	was	_	_	_	_
14-16	2807-2811	also	_	_	_	_
14-17	2812-2822	manifested	_	_	_	_
14-18	2823-2825	in	_	_	_	_
14-19	2826-2836	population	person|abstract[140]|event[141]	giv|new[140]|giv[141]	coref|coref	15-2[142_141]|15-23[151_0]
14-20	2837-2845	outreach	abstract[140]|event[141]	new[140]|giv[141]	_	_
14-21	2846-2855	screening	event[141]	giv[141]	_	_
14-22	2856-2857	.	_	_	_	_

#Text=In a street-based screening for hepatitis C virus ( HCV ) infection in drug users , the maneuver was excellently accepted by the target population .
15-1	2858-2860	In	_	_	_	_
15-2	2861-2862	a	event[142]	giv[142]	coref	20-12[199_142]
15-3	2863-2875	street-based	event[142]	giv[142]	_	_
15-4	2876-2885	screening	event[142]	giv[142]	_	_
15-5	2886-2889	for	event[142]	giv[142]	_	_
15-6	2890-2899	hepatitis	event[142]|abstract|abstract[147]	giv[142]|giv|new[147]	coref	19-24[189_147]
15-7	2900-2901	C	event[142]|person|abstract[145]|abstract[147]	giv[142]|new|new[145]|new[147]	appos	15-10[0_145]
15-8	2902-2907	virus	event[142]|abstract[145]|abstract[147]	giv[142]|new[145]|new[147]	_	_
15-9	2908-2909	(	event[142]|abstract[147]	giv[142]|new[147]	_	_
15-10	2910-2913	HCV	event[142]|abstract|abstract[147]	giv[142]|giv|new[147]	_	_
15-11	2914-2915	)	event[142]|abstract[147]	giv[142]|new[147]	_	_
15-12	2916-2925	infection	event[142]|abstract[147]	giv[142]|new[147]	_	_
15-13	2926-2928	in	event[142]|abstract[147]	giv[142]|new[147]	_	_
15-14	2929-2933	drug	event[142]|abstract[147]|substance|person[149]	giv[142]|new[147]|new|new[149]	_	_
15-15	2934-2939	users	event[142]|abstract[147]|person[149]	giv[142]|new[147]|new[149]	_	_
15-16	2940-2941	,	_	_	_	_
15-17	2942-2945	the	abstract[150]	new[150]	_	_
15-18	2946-2954	maneuver	abstract[150]	new[150]	_	_
15-19	2955-2958	was	_	_	_	_
15-20	2959-2970	excellently	_	_	_	_
15-21	2971-2979	accepted	_	_	_	_
15-22	2980-2982	by	_	_	_	_
15-23	2983-2986	the	person[151]	giv[151]	coref	21-23[213_151]
15-24	2987-2993	target	person[151]	giv[151]	_	_
15-25	2994-3004	population	person[151]	giv[151]	_	_
15-26	3005-3006	.	_	_	_	_

#Text=Various studies have reported the liver steatosis grading cut-off points of CAP score in patients with different liver disorders with satisfactory accuracy .
16-1	3007-3014	Various	abstract[152]	giv[152]	_	_
16-2	3015-3022	studies	abstract[152]	giv[152]	_	_
16-3	3023-3027	have	_	_	_	_
16-4	3028-3036	reported	_	_	_	_
16-5	3037-3040	the	abstract[157]	new[157]	_	_
16-6	3041-3046	liver	object|abstract[155]|abstract[157]	giv|new[155]|new[157]	coref	16-18
16-7	3047-3056	steatosis	abstract|abstract[155]|abstract[157]	giv|new[155]|new[157]	coref	17-33
16-8	3057-3064	grading	abstract[155]|abstract[157]	new[155]|new[157]	_	_
16-9	3065-3072	cut-off	abstract|abstract[157]	new|new[157]	_	_
16-10	3073-3079	points	abstract[157]	new[157]	_	_
16-11	3080-3082	of	abstract[157]	new[157]	_	_
16-12	3083-3086	CAP	abstract[157]|abstract|abstract[159]	new[157]|giv|giv[159]	_	_
16-13	3087-3092	score	abstract[157]|abstract[159]	new[157]|giv[159]	_	_
16-14	3093-3095	in	abstract[157]	new[157]	_	_
16-15	3096-3104	patients	abstract[157]|person[160]	new[157]|giv[160]	_	_
16-16	3105-3109	with	abstract[157]|person[160]	new[157]|giv[160]	_	_
16-17	3110-3119	different	abstract[157]|person[160]|abstract[162]	new[157]|giv[160]|giv[162]	coref	21-31[215_162]
16-18	3120-3125	liver	abstract[157]|person[160]|object|abstract[162]	new[157]|giv[160]|giv|giv[162]	coref	17-30
16-19	3126-3135	disorders	abstract[157]|person[160]|abstract[162]	new[157]|giv[160]|giv[162]	_	_
16-20	3136-3140	with	_	_	_	_
16-21	3141-3153	satisfactory	abstract[163]	new[163]	_	_
16-22	3154-3162	accuracy	abstract[163]	new[163]	_	_
16-23	3163-3164	.	_	_	_	_

#Text=Overall , FibroScan has a multitude of merits , such as being noninvasive , safe , fast , convenient , portable , and highly accurate in the assessment of liver stiffness and steatosis .
17-1	3165-3172	Overall	_	_	_	_
17-2	3173-3174	,	_	_	_	_
17-3	3175-3184	FibroScan	object	giv	coref	20-3[197_0]
17-4	3185-3188	has	_	_	_	_
17-5	3189-3190	a	abstract[165]	new[165]	_	_
17-6	3191-3200	multitude	abstract[165]	new[165]	_	_
17-7	3201-3203	of	abstract[165]	new[165]	_	_
17-8	3204-3210	merits	abstract[165]|abstract	new[165]|giv	_	_
17-9	3211-3212	,	_	_	_	_
17-10	3213-3217	such	_	_	_	_
17-11	3218-3220	as	_	_	_	_
17-12	3221-3226	being	_	_	_	_
17-13	3227-3238	noninvasive	_	_	_	_
17-14	3239-3240	,	_	_	_	_
17-15	3241-3245	safe	_	_	_	_
17-16	3246-3247	,	_	_	_	_
17-17	3248-3252	fast	_	_	_	_
17-18	3253-3254	,	_	_	_	_
17-19	3255-3265	convenient	_	_	_	_
17-20	3266-3267	,	_	_	_	_
17-21	3268-3276	portable	_	_	_	_
17-22	3277-3278	,	_	_	_	_
17-23	3279-3282	and	_	_	_	_
17-24	3283-3289	highly	_	_	_	_
17-25	3290-3298	accurate	_	_	_	_
17-26	3299-3301	in	_	_	_	_
17-27	3302-3305	the	abstract[167]	giv[167]	_	_
17-28	3306-3316	assessment	abstract[167]	giv[167]	_	_
17-29	3317-3319	of	abstract[167]	giv[167]	_	_
17-30	3320-3325	liver	abstract[167]|object|abstract[169]	giv[167]|giv|new[169]	coref	18-16
17-31	3326-3335	stiffness	abstract[167]|abstract[169]	giv[167]|new[169]	_	_
17-32	3336-3339	and	abstract[167]	giv[167]	_	_
17-33	3340-3349	steatosis	abstract[167]|abstract	giv[167]|giv	coref	18-16[176_0]
17-34	3350-3351	.	_	_	_	_

#Text=A previous study found that the grades based on abdominal ultrasonography gave accurate information regarding liver steatosis and MetS in nonalcoholic , healthy people .
18-1	3352-3353	A	abstract[171]	new[171]	_	_
18-2	3354-3362	previous	abstract[171]	new[171]	_	_
18-3	3363-3368	study	abstract[171]	new[171]	_	_
18-4	3369-3374	found	_	_	_	_
18-5	3375-3379	that	_	_	_	_
18-6	3380-3383	the	abstract[172]	new[172]	_	_
18-7	3384-3390	grades	abstract[172]	new[172]	_	_
18-8	3391-3396	based	abstract[172]	new[172]	_	_
18-9	3397-3399	on	abstract[172]	new[172]	_	_
18-10	3400-3409	abdominal	abstract[172]|object[173]	new[172]|new[173]	_	_
18-11	3410-3425	ultrasonography	abstract[172]|object[173]	new[172]|new[173]	_	_
18-12	3426-3430	gave	_	_	_	_
18-13	3431-3439	accurate	abstract[174]	new[174]	_	_
18-14	3440-3451	information	abstract[174]	new[174]	_	_
18-15	3452-3461	regarding	abstract[174]	new[174]	_	_
18-16	3462-3467	liver	abstract[174]|object|abstract[176]	new[174]|giv|giv[176]	coref|coref	19-20|19-37[193_176]
18-17	3468-3477	steatosis	abstract[174]|abstract[176]	new[174]|giv[176]	_	_
18-18	3478-3481	and	abstract[174]	new[174]	_	_
18-19	3482-3486	MetS	abstract[174]|abstract[177]	new[174]|giv[177]	coref	19-12[0_177]
18-20	3487-3489	in	abstract[174]|abstract[177]	new[174]|giv[177]	_	_
18-21	3490-3502	nonalcoholic	abstract[174]|abstract[177]|person[178]	new[174]|giv[177]|new[178]	coref	21-21[212_178]
18-22	3503-3504	,	abstract[174]|abstract[177]|person[178]	new[174]|giv[177]|new[178]	_	_
18-23	3505-3512	healthy	abstract[174]|abstract[177]|person[178]	new[174]|giv[177]|new[178]	_	_
18-24	3513-3519	people	abstract[174]|abstract[177]|person[178]	new[174]|giv[177]|new[178]	_	_
18-25	3520-3521	.	_	_	_	_

#Text=Moreover , considering the frequent coexistence and common pathological mechanisms of MetS and hepatopathy , such as steatohepatitis , liver inflammation , or the nonalcoholic fatty liver disease ( NAFLD ) , it was proposed that liver steatosis , especially NAFLD , could be a hepatic manifestation of MetS .
19-1	3522-3530	Moreover	_	_	_	_
19-2	3531-3532	,	_	_	_	_
19-3	3533-3544	considering	_	_	_	_
19-4	3545-3548	the	abstract[179]	new[179]	_	_
19-5	3549-3557	frequent	abstract[179]	new[179]	_	_
19-6	3558-3569	coexistence	abstract[179]	new[179]	_	_
19-7	3570-3573	and	_	_	_	_
19-8	3574-3580	common	abstract[180]	new[180]	_	_
19-9	3581-3593	pathological	abstract[180]	new[180]	_	_
19-10	3594-3604	mechanisms	abstract[180]	new[180]	_	_
19-11	3605-3607	of	abstract[180]	new[180]	_	_
19-12	3608-3612	MetS	abstract[180]|abstract|abstract[182]	new[180]|giv|giv[182]	coref|coref	19-12[182_0]|19-49[0_182]
19-13	3613-3616	and	abstract[180]|abstract[182]	new[180]|giv[182]	_	_
19-14	3617-3628	hepatopathy	abstract[180]|abstract[182]|abstract	new[180]|giv[182]|new	_	_
19-15	3629-3630	,	abstract[180]	new[180]	_	_
19-16	3631-3635	such	abstract[180]	new[180]	_	_
19-17	3636-3638	as	abstract[180]	new[180]	_	_
19-18	3639-3654	steatohepatitis	abstract[180]|abstract	new[180]|new	_	_
19-19	3655-3656	,	abstract[180]	new[180]	_	_
19-20	3657-3662	liver	abstract[180]|object|event[186]	new[180]|giv|new[186]	coref	19-27
19-21	3663-3675	inflammation	abstract[180]|event[186]	new[180]|new[186]	_	_
19-22	3676-3677	,	abstract[180]	new[180]	_	_
19-23	3678-3680	or	abstract[180]	new[180]	_	_
19-24	3681-3684	the	abstract[180]|abstract[189]	new[180]|giv[189]	appos	19-30[0_189]
19-25	3685-3697	nonalcoholic	abstract[180]|abstract[189]	new[180]|giv[189]	_	_
19-26	3698-3703	fatty	abstract[180]|abstract|abstract[189]	new[180]|new|giv[189]	_	_
19-27	3704-3709	liver	abstract[180]|object|abstract[189]	new[180]|giv|giv[189]	coref	19-37
19-28	3710-3717	disease	abstract[180]|abstract[189]	new[180]|giv[189]	_	_
19-29	3718-3719	(	_	_	_	_
19-30	3720-3725	NAFLD	abstract	giv	ana	19-33
19-31	3726-3727	)	_	_	_	_
19-32	3728-3729	,	_	_	_	_
19-33	3730-3732	it	abstract	giv	_	_
19-34	3733-3736	was	_	_	_	_
19-35	3737-3745	proposed	_	_	_	_
19-36	3746-3750	that	_	_	_	_
19-37	3751-3756	liver	object|abstract[193]	giv|giv[193]	appos	19-40[194_193]
19-38	3757-3766	steatosis	abstract[193]	giv[193]	_	_
19-39	3767-3768	,	_	_	_	_
19-40	3769-3779	especially	abstract[194]	giv[194]	coref	19-45[195_194]
19-41	3780-3785	NAFLD	abstract[194]	giv[194]	_	_
19-42	3786-3787	,	_	_	_	_
19-43	3788-3793	could	_	_	_	_
19-44	3794-3796	be	_	_	_	_
19-45	3797-3798	a	abstract[195]	giv[195]	_	_
19-46	3799-3806	hepatic	abstract[195]	giv[195]	_	_
19-47	3807-3820	manifestation	abstract[195]	giv[195]	_	_
19-48	3821-3823	of	abstract[195]	giv[195]	_	_
19-49	3824-3828	MetS	abstract[195]|abstract	giv[195]|giv	coref	20-16
19-50	3829-3830	.	_	_	_	_

#Text=Therefore , the FibroScan is investigated to be an option for the frontline screening of MetS in participants of a self-paid health examination in Taiwan .
20-1	3831-3840	Therefore	_	_	_	_
20-2	3841-3842	,	_	_	_	_
20-3	3843-3846	the	object[197]	giv[197]	coref	21-18[0_197]
20-4	3847-3856	FibroScan	object[197]	giv[197]	_	_
20-5	3857-3859	is	_	_	_	_
20-6	3860-3872	investigated	_	_	_	_
20-7	3873-3875	to	_	_	_	_
20-8	3876-3878	be	_	_	_	_
20-9	3879-3881	an	abstract[198]	new[198]	_	_
20-10	3882-3888	option	abstract[198]	new[198]	_	_
20-11	3889-3892	for	abstract[198]	new[198]	_	_
20-12	3893-3896	the	abstract[198]|event[199]	new[198]|giv[199]	coref	22-12[0_199]
20-13	3897-3906	frontline	abstract[198]|event[199]	new[198]|giv[199]	_	_
20-14	3907-3916	screening	abstract[198]|event[199]	new[198]|giv[199]	_	_
20-15	3917-3919	of	abstract[198]|event[199]	new[198]|giv[199]	_	_
20-16	3920-3924	MetS	abstract[198]|event[199]|abstract	new[198]|giv[199]|giv	coref	21-35
20-17	3925-3927	in	abstract[198]	new[198]	_	_
20-18	3928-3940	participants	abstract[198]|person[201]	new[198]|new[201]	_	_
20-19	3941-3943	of	abstract[198]|person[201]	new[198]|new[201]	_	_
20-20	3944-3945	a	abstract[198]|person[201]|event[203]	new[198]|new[201]|new[203]	_	_
20-21	3946-3955	self-paid	abstract[198]|person[201]|event[203]	new[198]|new[201]|new[203]	_	_
20-22	3956-3962	health	abstract[198]|person[201]|abstract|event[203]	new[198]|new[201]|new|new[203]	_	_
20-23	3963-3974	examination	abstract[198]|person[201]|event[203]	new[198]|new[201]|new[203]	_	_
20-24	3975-3977	in	abstract[198]|person[201]|event[203]	new[198]|new[201]|new[203]	_	_
20-25	3978-3984	Taiwan	abstract[198]|person[201]|event[203]|place	new[198]|new[201]|new[203]|new	_	_
20-26	3985-3986	.	_	_	_	_

#Text=To the best of our knowledge , this is the first study to explore the utility of FibroScan in identifying people from the general population who have physical status and disorders that fulfill the MetS criteria .
21-1	3987-3989	To	_	_	_	_
21-2	3990-3993	the	abstract[205]	new[205]	_	_
21-3	3994-3998	best	abstract[205]	new[205]	_	_
21-4	3999-4001	of	abstract[205]	new[205]	_	_
21-5	4002-4005	our	abstract[205]|person|abstract[207]	new[205]|acc|new[207]	ana	21-8[0_207]
21-6	4006-4015	knowledge	abstract[205]|abstract[207]	new[205]|new[207]	_	_
21-7	4016-4017	,	_	_	_	_
21-8	4018-4022	this	abstract	giv	coref	21-10[209_0]
21-9	4023-4025	is	_	_	_	_
21-10	4026-4029	the	abstract[209]	giv[209]	_	_
21-11	4030-4035	first	abstract[209]	giv[209]	_	_
21-12	4036-4041	study	abstract[209]	giv[209]	_	_
21-13	4042-4044	to	abstract[209]	giv[209]	_	_
21-14	4045-4052	explore	abstract[209]	giv[209]	_	_
21-15	4053-4056	the	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
21-16	4057-4064	utility	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
21-17	4065-4067	of	abstract[209]|abstract[210]	giv[209]|new[210]	_	_
21-18	4068-4077	FibroScan	abstract[209]|abstract[210]|object	giv[209]|new[210]|giv	_	_
21-19	4078-4080	in	_	_	_	_
21-20	4081-4092	identifying	_	_	_	_
21-21	4093-4099	people	person[212]	giv[212]	_	_
21-22	4100-4104	from	person[212]	giv[212]	_	_
21-23	4105-4108	the	person[212]|person[213]	giv[212]|giv[213]	_	_
21-24	4109-4116	general	person[212]|person[213]	giv[212]|giv[213]	_	_
21-25	4117-4127	population	person[212]|person[213]	giv[212]|giv[213]	_	_
21-26	4128-4131	who	person[212]	giv[212]	_	_
21-27	4132-4136	have	person[212]	giv[212]	_	_
21-28	4137-4145	physical	person[212]|abstract[214]	giv[212]|new[214]	_	_
21-29	4146-4152	status	person[212]|abstract[214]	giv[212]|new[214]	_	_
21-30	4153-4156	and	person[212]	giv[212]	_	_
21-31	4157-4166	disorders	person[212]|abstract[215]	giv[212]|giv[215]	_	_
21-32	4167-4171	that	person[212]|abstract[215]	giv[212]|giv[215]	_	_
21-33	4172-4179	fulfill	person[212]|abstract[215]	giv[212]|giv[215]	_	_
21-34	4180-4183	the	person[212]|abstract[215]|abstract[217]	giv[212]|giv[215]|new[217]	_	_
21-35	4184-4188	MetS	person[212]|abstract[215]|abstract|abstract[217]	giv[212]|giv[215]|giv|new[217]	coref	22-14
21-36	4189-4197	criteria	person[212]|abstract[215]|abstract[217]	giv[212]|giv[215]|new[217]	_	_
21-37	4198-4199	.	_	_	_	_

#Text=A subsequent objective was to explore its feasibility and reliability in screening for MetS without performing any simultaneous invasive procedures , such as blood assays .
22-1	4200-4201	A	abstract[218]	new[218]	ana	22-7[0_218]
22-2	4202-4212	subsequent	abstract[218]	new[218]	_	_
22-3	4213-4222	objective	abstract[218]	new[218]	_	_
22-4	4223-4226	was	_	_	_	_
22-5	4227-4229	to	_	_	_	_
22-6	4230-4237	explore	_	_	_	_
22-7	4238-4241	its	abstract|abstract[220]	giv|new[220]	_	_
22-8	4242-4253	feasibility	abstract[220]	new[220]	_	_
22-9	4254-4257	and	_	_	_	_
22-10	4258-4269	reliability	abstract	giv	_	_
22-11	4270-4272	in	_	_	_	_
22-12	4273-4282	screening	event	giv	_	_
22-13	4283-4286	for	_	_	_	_
22-14	4287-4291	MetS	abstract	giv	_	_
22-15	4292-4299	without	_	_	_	_
22-16	4300-4310	performing	_	_	_	_
22-17	4311-4314	any	abstract[224]	giv[224]	_	_
22-18	4315-4327	simultaneous	abstract[224]	giv[224]	_	_
22-19	4328-4336	invasive	abstract[224]	giv[224]	_	_
22-20	4337-4347	procedures	abstract[224]	giv[224]	_	_
22-21	4348-4349	,	abstract[224]	giv[224]	_	_
22-22	4350-4354	such	abstract[224]	giv[224]	_	_
22-23	4355-4357	as	abstract[224]	giv[224]	_	_
22-24	4358-4363	blood	abstract[224]|substance|abstract[226]	giv[224]|giv|giv[226]	_	_
22-25	4364-4370	assays	abstract[224]|abstract[226]	giv[224]|giv[226]	_	_
22-26	4371-4372	.	_	_	_	_
